Literature DB >> 9373306

Immunotherapy of cancer by peptide-based vaccines for the induction of tumor-specific T cell immunity.

M E Ressing1, R Offringa, R E Toes, F Ossendorp, J H de Jong, R M Brandt, W M Kast, C J Melief.   

Abstract

Recent progress in defining the molecular nature of antigens and in finding ways to manipulate T cell-mediated immune responses may provide new modalities for cancer treatment. In this report, we review preclinical studies as well as the first clinical trials with vaccination strategies aiming at the induction of anti-tumor immunity. In particular, we focus on the development of a vaccine against human papillomavirus-induced cervical carcinoma.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9373306     DOI: 10.1016/s1380-2933(96)00057-7

Source DB:  PubMed          Journal:  Immunotechnology        ISSN: 1380-2933


  4 in total

Review 1.  Prospects for the therapeutic use of anticancer vaccines.

Authors:  R S Chamberlain
Journal:  Drugs       Date:  1999-03       Impact factor: 9.546

Review 2.  Sipuleucel-T: harbinger of a new age of therapeutics for prostate cancer.

Authors:  Ravi A Madan; James L Gulley
Journal:  Expert Rev Vaccines       Date:  2011-02       Impact factor: 5.217

3.  Limitations of HLA-transgenic mice in presentation of HLA-restricted cytotoxic T-cell epitopes from endogenously processed human papillomavirus type 16 E7 protein.

Authors:  Michael D Street; Tracy Doan; Karen A Herd; Robert W Tindle
Journal:  Immunology       Date:  2002-08       Impact factor: 7.397

4.  The influence of human papillomavirus type and HIV status on the lymphomononuclear cell profile in patients with cervical intraepithelial lesions of different severity.

Authors:  Maria Alice G Gonçalves; Edson G Soares; Eduardo A Donadi
Journal:  Infect Agent Cancer       Date:  2009-08-18       Impact factor: 2.965

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.